Zevra Therapeutics (ZVRA) Shares Outstanding (Weighted Average) (2014 - 2026)

Zevra Therapeutics has reported Shares Outstanding (Weighted Average) for 13 years, with the latest figure at $58.4 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 7.97% year-over-year to $58.4 million; the trailing twelve-month figure through Mar 2026 stood at $58.4 million (up 7.97% YoY), and the FY2025 full-year result was $55.3 million, up 19.59% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $58.4 million, up from $55.3 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $58.4 million in Q1 2026, with the low at $5.6 million in Q1 2024.
• Historically, Shares Outstanding (Weighted Average) has averaged $40.9 million across 5 years, with a median of $35.5 million in 2023.
• Annual changes were most pronounced in 2024 — Shares Outstanding (Weighted Average) plunged 83.74% — and 2025, when it surged 865.36%.
• Zevra Therapeutics' Shares Outstanding (Weighted Average) stood at $34.5 million in 2022, then climbed by 2.79% to $35.5 million in 2023, then surged by 30.46% to $46.3 million in 2024, then advanced by 19.59% to $55.3 million in 2025, then climbed by 5.6% to $58.4 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $58.4 million (Q1 2026), $55.3 million (Q4 2025), and $56.0 million (Q3 2025), per Business Quant data.